
  
    
      
        Introduction_NNP
        Antiretroviral_NNP therapy_NN (_( ART_NNP )_) has_VBZ been_VBN a_DT milestone_NN in_IN the_DT treatment_NN of_IN HIV_NNP infection_NN ._.
        Current_JJ treatment_NN guidelines_NNS for_IN HIV-_NNP 1_CD infection_NN in_IN the_DT United_NNP States_NNPS recommend_VBP the_DT
        initiation_NN of_IN ART_NNP in_IN patients_NNS with_IN CD_NNP 4_CD T_NN cell_NN counts_NNS of_IN less_JJR than_IN 350_CD cells_NNS /_NN μl_NN [_NN 1_CD ]_NN ._. In_IN
        implementing_VBG these_DT guidelines_NNS ,_, health-care_NN providers_NNS face_VBP the_DT ongoing_JJ challenge_NN of_IN
        developing_VBG treatment_NN strategies_NNS that_WDT minimize_VB drug-related_JJ toxicity_NN and_CC adverse_JJ effects_NNS
        while_IN retaining_VBG effective_JJ control_NN of_IN viral_JJ replication_NN ._. Furthermore_RB ,_, treatment-associated_JJ
        costs_NNS (_( particularly_RB in_IN resource-poor_JJ areas_NNS )_) ,_, difficulty_NN in_IN maintaining_VBG long-term_JJ optimal_NN
        adherence_NN [_NN 2_CD ]_NN ,_, and_CC the_DT emergence_NN of_IN viral_JJ resistance_NN [_NN 3_CD ,_, 4_CD ,_, 5_CD ]_NN have_VBP limited_VBD the_DT feasibility_NN
        of_IN life-long_JJ ART-mediated_NNP viral_JJ suppression_NN ,_, increasing_VBG the_DT need_NN for_IN alternative_JJ treatment_NN
        strategies_NNS ._. Intermittent_NNP therapy_NN strategies_NNS ,_, consisting_VBG of_IN alternating_VBG cycles_NNS on_IN and_CC off_RP
        ART_NNP ,_, have_VBP increasingly_RB emerged_VBN as_IN a_DT potential_JJ intervention_NN to_TO address_VB limitations_NNS of_IN
        continuous_JJ ART_NNP [_NN 6_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ]_NN ._. Therapy_NNP interruption_NN (_( TI_NNP )_) studies_NNS in_IN ART-treated_NNP patients_NNS with_IN
        suppressed_VBN HIV_NNP infection_NN [_NN 10_CD ]_NN have_VBP addressed_VBN the_DT general_JJ questions_NNS as_IN to_TO whether_IN such_JJ
        strategies_NNS can_MD achieve_VB greater_JJR viral_JJ control_NN through_IN increased_VBN antiviral_JJ responses_NNS
        (_( autoimmunization_NN hypothesis_NNS )_) or_CC simply_RB serve_VB as_IN a_DT strategy_NN to_TO reduce_VB cost_NN of_IN long-term_JJ
        therapy_NN and_CC drug-associated_JJ toxicity_NN ._. While_IN pilot_NN studies_NNS and_CC uncontrolled_JJ (_( or_CC incomplete_JJ )_)
        trials_NNS in_IN patients_NNS with_IN chronic_JJ HIV_NNP infection_NN have_VBP addressed_VBN viral_JJ and_CC immune_JJ outcomes_NNS of_IN
        fixed-length_JJ TI_NNP and_CC fixed_VBN on-drug_JJ cycles_NNS [_NN 11_CD ,_, 12_CD ,_, 13_CD ,_, 14_CD ,_, 15_CD ,_, 16_CD ]_NN ,_, no_DT completed_VBN randomized_JJ ,_,
        controlled_VBN trial_NN has_VBZ yet_RB addressed_VBN by_IN intent-to-treat_JJ analysis_NN the_DT outcome_NN during_IN an_DT
        open-ended_JJ TI_NNP of_IN sequential_NN TIs_NNP versus_CC continuous_JJ treatment_NN in_IN patients_NNS with_IN confirmed_VBD
        suppression_NN ._. The_DT largest_JJS study_NN to_TO date_NN in_IN this_DT area_NN is_VBZ the_DT prospective_JJ single-arm_JJ
        Swiss–_NNP Spanish_NNP Intermittent_NNP Trial_NNP (_( SSITT_NNP )_) conducted_VBN in_IN 133_CD recruited_VBN patients_NNS undergoing_VBG
        sequential_NN 2_CD -_: wk_NN TIs_NNP and_CC showing_VBG a_DT lack_NN of_IN impact_NN of_IN this_DT strategy_NN on_IN achieving_VBG sustained_VBN
        viral_JJ loads_NNS of_IN less_JJR than_IN 5_CD ,_, 000_CD copies_NNS /_NN ml_NN off_IN therapy_NN in_IN those_DT that_WDT completed_VBD the_DT study_NN
        [_NN 11_CD ]_NN ._. However_RB ,_, the_DT lack_NN of_IN a_DT control_NN arm_NN in_IN this_DT study_NN has_VBZ left_VBN unanswered_JJ questions_NNS about_IN
        the_DT impact_NN of_IN multiple_JJ TIs_NNP on_IN time_NN to_TO rebound_VB ,_, immune_JJ reconstitution_NN ,_, therapy_NN failure_NN ,_, and_CC
        viral_JJ resistance_NN when_WRB analyzed_VBD against_IN a_DT randomized_JJ control_NN arm_NN of_IN continuous_JJ treatment_NN
        followed_VBN for_IN equal_JJ time_NN before_IN a_DT single_JJ open-ended_JJ interruption_NN ._.
        We_PRP completed_VBD a_DT randomized_JJ ,_, controlled_VBN trial_NN on_IN the_DT outcome_NN of_IN repeated_VBN 2_CD -_: to_TO 6_CD -_: wk_NN TIs_NNP in_IN
        patients_NNS with_IN chronic_JJ infection_NN in_IN which_WDT the_DT comparator_NN group_NN maintained_VBD continuous_JJ therapy_NN
        and_CC then_RB an_DT open-ended_JJ interruption_NN period_NN was_VBD applied_VBN in_IN both_DT treatment_NN groups_NNS ._. The_DT study_NN
        addressed_VBD the_DT potential_NN for_IN repeated_VBN interruptions_NNS of_IN therapy_NN to_TO delay_VB time_NN to_TO viral_JJ
        rebound_NN as_IN a_DT primary_JJ outcome_NN and_CC analyzed_VBD secondary_JJ outcomes_NNS regarding_VBG study-defined_JJ safety_NN
        criteria_NNS ,_, viral_JJ suppression_NN and_CC resistance_NN ,_, and_CC retention_NN of_IN immune_JJ reconstitution_NN ._.
      
      
        Methods_NNP
        
          Participants_NNS
          Between_IN August_NNP 2000_CD and_CC December_NNP 2003_CD ,_, we_PRP enrolled_VBD 42_CD patients_NNS infected_VBN with_IN HIV_NNP who_WP
          were_VBD older_JJR than_IN 18_CD y_NN and_CC on_IN ART_NNP ;_: eligibility_NN criteria_NNS included_VBD CD_NNP 4_CD counts_NNS of_IN greater_JJR than_IN
          400_CD cells_NNS /_NN μl_NN on_IN ART_NNP with_IN a_DT nadir_NN of_IN no_RB less_JJR than_IN 100_CD cells_NNS /_NN μl_NN ,_, ART-mediated_NNP suppression_NN
          (_( <_NN 500_CD copies_NNS /_NN ml_NN )_) for_IN more_JJR than_IN 6_CD mo_NN and_CC less_JJR than_IN 50_CD copies_NNS /_NN ml_NN at_IN recruitment_NN on_IN any_DT
          antiretroviral_NN regimen_NN ._. Approval_NNP of_IN the_DT study_NN protocol_NN was_VBD obtained_VBN from_IN the_DT
          institutional_JJ review_NN board_NN (_( IRB_NNP )_) of_IN the_DT Philadelphia_NNP Field_NNP Initiating_NNP Group_NNP for_IN HIV_NNP
          Trials_NNP (_( Philadelphia_NNP ,_, Pennsylvania_NNP ,_, United_NNP States_NNPS )_) ._. Written_VBN informed_VBN consent_NN was_VBD obtained_VBN
          from_IN all_DT patients_NNS ._. Human_JJ experimentation_NN guidelines_NNS of_IN the_DT United_NNP States_NNP Department_NNP of_IN
          Health_NNP and_CC Human_NNP Services_NNP and_CC of_IN the_DT authors_NNS '_POS institutions_NNS were_VBD followed_VBN ._. The_DT study_NN
          protocol_NN ,_, including_VBG the_DT patient_NN consent_NN form_NN ,_, the_DT CONSORT_NNP form_NN ,_, and_CC the_DT IRB_NNP approval_NN ,_, can_MD
          be_VB found_VBN in_IN Protocols_NNP S_NNP 1_CD –_NN S_NNP 4_CD ._.
        
        
          Randomization_NNP and_CC Study_NNP Design_NNP
          Forty-two_NNP eligible_JJ patients_NNS from_IN the_DT Jonathan_NNP Lax_NNP Immune_NNP Disorder_NNP Clinic_NNP in_IN
          Philadelphia_NNP ,_, Pennsylvania_NNP ,_, were_VBD randomized_JJ via_IN sealed_VBN envelopes_NNS in_IN a_DT 1_CD :_: 1_CD fashion_NN to_TO a_DT
          first_JJ phase_NN (_( phase_NN I_PRP )_) of_IN either_DT (_( 1_LS )_) three_CD successive_JJ TIs_NNP of_IN 2_CD ,_, 4_CD ,_, and_CC 6_CD wk_NN ,_, respectively_RB ,_,
          or_CC (_( 2_LS )_) maintenance_NN of_IN ART_NNP for_IN 40_CD wk_NN before_IN a_DT final_JJ interruption_NN of_IN therapy_NN in_IN both_DT arms_NNS
          (_( phase_NN II_NNP )_) subject_JJ to_TO therapy_NN reinitiation_NN criteria_NNS as_IN described_VBN below_IN ._. Phase_NN II_NNP
          consisted_VBD of_IN an_DT open-ended_JJ interruption_NN to_TO allow_VB for_IN virological_JJ and_CC immunological_JJ
          comparisons_NNS between_IN the_DT groups_NNS off_IN therapy_NN ._. Study_NN visits_NNS were_VBD every_DT 2_CD wk_NN for_IN the_DT repeated_VBN
          interruptions_NNS group_NN and_CC every_DT 4_CD wk_NN for_IN the_DT continuous_JJ ART_NNP group_NN during_IN phase_NN I_PRP ._. Both_DT
          groups_NNS were_VBD followed_VBN every_DT 2_CD wk_NN during_IN phase_NN II_NNP ._. We_PRP followed_VBD a_DT study_NN design_NN with_IN
          step-wise_JJ increases_NNS in_IN the_DT length_NN of_IN TI_NNP cycles_NNS to_TO address_VB potential_JJ safety_NN concerns_NNS
          (_( resuppression_NN was_VBD confirmed_VBN after_IN shorter_JJR TIs_NNP before_IN longer_JJR interruptions_NNS were_VBD
          initiated_VBN )_) and_CC the_DT hypothesis_NNS that_WDT sequential_NN viral_JJ replication_NN intervals_NNS would_MD stimulate_VB
          viral_JJ control_NN and_CC a_DT delay_NN in_IN time_NN to_TO viral_JJ rebound_NN ._.
          Phase_NN I_PRP procedures_NNS for_IN the_DT repeated_VBN interruptions_NNS group_NN included_VBD the_DT following_VBG ._. (_( 1_LS )_)
          Interruption_NNP of_IN therapy_NN was_VBD individually_RB timed_VBN to_TO occur_VB after_IN two_CD HIV_NNP RNA_NNP measurements_NNS of_IN
          less_JJR than_IN 50_CD copies_NNS /_NN ml_NN without_IN any_DT viral_JJ load_NN measurements_NNS greater_JJR than_IN 400_CD copies_NNS /_NN ml_NN in_IN
          between_IN ;_: these_DT interruptions_NNS increased_VBN from_IN 2_CD to_TO 4_CD to_TO 6_CD wk_NN sequentially_RB ._. (_( 2_LS )_) If_IN a_DT 0_CD ._. 5_CD -_: log_VB
          or_CC greater_JJR reduction_NN in_IN viral_JJ load_NN did_VBD not_RB occur_VB by_IN 6_CD wk_NN of_IN reinitiated_JJ therapy_NN or_CC less_JJR
          than_IN 50_CD copies_NNS /_NN ml_NN was_VBD not_RB achieved_VBN within_IN 20_CD wk_NN of_IN reinitiated_JJ therapy_NN ,_, patients_NNS were_VBD
          withdrawn_VBN as_IN therapy_NN failures_NNS and_CC a_DT resistance_NN test_NN was_VBD performed_VBN ._. (_( 3_LS )_) Patients_NNPS were_VBD also_RB
          withdrawn_VBN as_IN therapy_NN failures_NNS if_IN (_( a_DT )_) the_DT CD_NNP 4_CD cell_NN number_NN declined_VBN by_IN more_JJR than_IN 45_CD %_NN of_IN the_DT
          baseline_JJ CD_NNP 4_CD count_NN ,_, (_( b_SYM )_) participants_NNS developed_VBD an_DT opportunistic_JJ infection_NN ,_, even_RB if_IN
          retaining_VBG required_VBN CD_NNP 4_CD count_NN levels_NNS ,_, or_CC (_( c_SYM )_) a_DT viral_JJ load_NN of_IN greater_JJR than_IN 500_CD ,_, 000_CD
          copies_NNS /_NN ml_NN occurred_VBD once_RB ,_, with_IN or_CC without_IN development_NN of_IN acute_JJ retroviral_NN syndrome_NN as_IN
          defined_VBN by_IN fever_NN ,_, skin_NN lesions_NNS ,_, and_CC pharyngitis_NNS ._.
          Phase_NN I_PRP procedures_NNS for_IN the_DT continuous_JJ therapy_NN arm_NN included_VBD the_DT following_VBG :_: (_( 1_LS )_) patient_NN
          monitoring_VBG if_IN detected_VBD viremia_NN was_VBD between_IN 50_CD and_CC 999_CD copies_NNS /_NN ml_NN ,_, with_IN the_DT patient_NN
          withdrawn_VBN if_IN their_PRP$ viral_JJ load_NN did_VBD not_RB return_VB to_TO less_JJR than_IN 50_CD copies_NNS /_NN ml_NN immediately_RB prior_RB
          to_TO phase_VB II_NNP ,_, and_CC (_( 2_LS )_) patient_NN study_NN withdrawal_NN as_IN therapy_NN failure_NN if_IN during_IN the_DT 40_CD -_: wk_NN ART_NNP
          period_NN viral_JJ load_NN rebounded_VBD to_TO more_JJR than_IN 1_CD ,_, 000_CD copies_NNS /_NN ml_NN at_IN two_CD consecutive_JJ time_NN
          points_NNS ._.
          Phase_NN II_NNP procedures_NNS for_IN both_DT arms_NNS included_VBD the_DT following_VBG :_: (_( 1_LS )_) monitoring_VBG for_IN patient_NN
          study_NN withdrawal_NN criteria_NNS as_IN described_VBN in_IN phase_NN I_PRP ,_, (_( 2_LS )_) determining_VBG time_NN to_TO primary_JJ end_NN
          point_NN of_IN a_DT viral_JJ load_NN greater_JJR than_IN 5_CD ,_, 000_CD copies_NNS /_NN ml_NN ,_, (_( 3_LS )_) monitoring_VBG until_IN the_DT time_NN of_IN
          therapy_NN reinitiation_NN at_IN a_DT viral_JJ load_NN greater_JJR than_IN 30_CD ,_, 000_CD copies_NNS /_NN ml_NN for_IN three_CD consecutive_JJ
          time_NN points_NNS ,_, and_CC (_( 4_LS )_) after_IN reinitiation_NN of_IN therapy_NN ,_, follow-up_JJ on_IN therapy_NN to_TO confirm_VB
          resuppression_NN to_TO less_JJR than_IN 50_CD copies_NNS /_NN ml_NN at_IN 6_CD ,_, 10_CD ,_, and_CC 14_CD wk_NN on_IN therapy_NN ._. Clinical_NNP and_CC
          laboratory_NN parameters_NNS (_( CD_NNP 4_CD count_NN and_CC viral_JJ load_NN )_) were_VBD monitored_VBN at_IN each_DT visit_NN ,_, and_CC venous_JJ
          blood_NN was_VBD collected_VBN for_IN additional_JJ secondary_JJ outcomes_NNS during_IN selected_VBN study_NN visits_NNS ._.
          In_IN both_DT phase_NN I_PRP and_CC II_NNP ,_, participants_NNS taking_VBG non-nucleoside_JJ reverse-transcriptase_JJ
          inhibitors_NNS (_( NNRTIs_NNP )_) were_VBD instructed_VBN to_TO stop_VB them_PRP a_DT day_NN earlier_RBR than_IN the_DT remaining_VBG drugs_NNS
          in_IN the_DT regimen_NN ._.
        
        
          Primary_JJ and_CC Secondary_JJ Outcomes_NNP
          The_DT primary_JJ outcome_NN was_VBD time_NN to_TO confirmed_VBD virological_JJ rebound_NN during_IN phase_NN II_NNP ._. Rebound_NNP
          was_VBD defined_VBN as_IN first_JJ time_NN point_NN with_IN greater_JJR than_IN 5_CD ,_, 000_CD copies_NNS /_NN ml_NN ._. Viral_NNP replication_NN
          magnitude_NN as_IN defined_VBN by_IN mean_NN HIV-_NNP 1_CD plasma_NN RNA_NNP area_NN under_IN the_DT curve_NN (_( AUC_NNP
          HIV_NNP RNA_NNP )_) was_VBD measured_VBN as_IN a_DT secondary_JJ outcome_NN at_IN weeks_NNS 12_CD and_CC 20_CD of_IN
          phase_NN II_NNP based_VBN on_IN reinitiation-of-therapy_JJ criteria_NNS outlined_VBN above_IN ._.
          Additional_JJ secondary_JJ outcomes_NNS included_VBD (_( 1_LS )_) safety_NN outcomes_NNS (_( serious_JJ adverse_JJ events_NNS
          [_NN SAEs_NNP ]_NN and_CC patient_NN withdrawal_NN based_VBN on_IN criteria_NNS defined_VBN above_IN )_) ,_, (_( 2_LS )_) retention_NN of_IN
          ART-mediated_NNP immune_JJ reconstitution_NN ,_, and_CC (_( 3_LS )_) detection_NN of_IN viral_JJ resistance_NN ._. Retention_NNP of_IN
          immune_JJ reconstitution_NN was_VBD analyzed_VBN by_IN (_( 1_LS )_) same-day_JJ whole_JJ blood_NN flow-cytometry-based_JJ
          analysis_NN of_IN CD_NNP 4_CD and_CC CD_NNP 8_CD T_NN cells_NNS ,_, including_VBG total_NN and_CC naïve_NN (_( CD_NNP 62_CD l_NN /_NN CD_NNP 45_CD RA_NNP )_) and_CC memory_NN
          (_( CD_NNP 45_CD RO_NNP )_) subsets_NNS as_IN described_VBN [_NN 17_CD ]_NN ,_, and_CC (_( 2_LS )_) same-day_JJ recall_NN response_NN analysis_NN of_IN
          peripheral_JJ blood_NN mononuclear_NN cell_NN lymphoproliferative_JJ responses_NNS to_TO 
          Candida_NNP albicans_NNS as_IN described_VBN [_NN 17_CD ]_NN ._. Viral_NNP resistance_NN mutations_NNS
          were_VBD retrospectively_RB analyzed_VBN on_IN cryopreserved_JJ plasma_NN samples_NNS by_IN genotyping_VBG of_IN first_JJ
          available_JJ sample_NN with_IN viral_JJ load_NN greater_JJR than_IN 100_CD copies_NNS /_NN ml_NN following_VBG each_DT interruption_NN
          using_VBG the_DT TruGene_NNP Assay_NNP (_( Visible_NNP Genetics_NNP ,_, Toronto_NNP ,_, Canada_NNP )_) at_IN the_DT Gladstone_NNP Institute_NNP of_IN
          Virology_NNP and_CC Immunology_NNP (_( San_NNP Francisco_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) as_RB previously_RB
          described_VBD [_NN 18_CD ,_, 19_CD ]_NN ._.
        
        
          Sample_NNP Size_NN
          The_DT sample_NN size_NN required_VBN was_VBD calculated_VBN using_VBG PS_NNP [_NN 20_CD ]_NN software_NN ,_, and_CC based_VBN on_IN a_DT type_NN I_PRP
          error_NN of_IN 0_CD ._. 05_CD ,_, with_IN 90_CD %_NN power_NN ,_, to_TO detect_VB a_DT difference_NN of_IN 4_CD wk_NN or_CC more_JJR in_IN time_NN to_TO viral_JJ
          rebound_NN between_IN arms_NNS ._. Eighteen_CD patients_NNS per_IN group_NN resulted_VBD in_IN sufficient_JJ power_NN (_( 18_CD for_IN
          90_CD %_NN ,_, 13_CD for_IN 80_CD %_NN )_) to_TO determine_VB a_DT difference_NN of_IN 4_CD wk_NN or_CC greater_JJR between_IN groups_NNS in_IN time_NN to_TO
          rebound_NN of_IN virus_NN during_IN the_DT open-ended_JJ interruption_NN ._. Assuming_VBG a_DT loss_NN to_TO follow-up_JJ of_IN 15_CD %_NN ,_,
          we_PRP targeted_VBD 21_CD patients_NNS per_IN group_NN ,_, or_CC 42_CD total_JJ ._.
        
        
          Statistical_NNP Analysis_NNP
          The_DT primary_JJ analysis_NN was_VBD an_DT intent-to-treat_JJ analysis_NN in_IN which_WDT dropouts_NNS were_VBD assigned_VBN a_DT
          week_NN 0_CD rebound_NN time_NN (_( e_SYM ._. g_SYM ._. ,_, maximum_NN failure_NN to_TO delay_VB rebound_NN )_) ._. In_IN secondary_JJ analyses_NNS ,_,
          these_DT dropouts_NNS were_VBD excluded_VBN ._. The_DT log-rank_JJ test_NN was_VBD used_VBN to_TO test_VB the_DT null_NN hypothesis_NNS of_IN
          no_DT difference_NN between_IN arms_NNS in_IN the_DT number_NN of_IN weeks_NNS from_IN initiation_NN of_IN the_DT open-ended_JJ TI_NNP to_TO
          reaching_VBG viral_JJ rebound_NN as_IN defined_VBN ._. Patients_NNS not_RB reaching_VBG end_NN point_NN at_IN 26_CD wk_NN after_IN the_DT
          beginning_NN of_IN the_DT open-ended_JJ TI_NNP were_VBD censored_VBN ._. Wilcoxon_NNP rank_NN sum_NN tests_NNS were_VBD used_VBN to_TO
          compare_VB baseline_NN and_CC week_NN 0_CD of_IN the_DT open-ended_JJ interruption_NN between_IN groups_NNS ._. Wilcoxon_NNP
          signed_VBD rank_NN tests_NNS were_VBD used_VBN to_TO test_VB for_IN no_DT change_NN from_IN baseline_NN to_TO week_NN 0_CD of_IN phase_NN II_NNP ._.
          Finally_RB ,_, Wilcoxon_NNP rank_NN sum_NN tests_NNS were_VBD employed_VBN to_TO test_VB between_IN groups_NNS for_IN equality_NN of_IN the_DT
          mean_NN AUC_NNP
          HIV_NNP RNA_NNP up_IN to_TO 12_CD and_CC 20_CD wk_NN ._. In_IN all_DT cases_NNS ,_, a_DT two-sided_JJ alpha_NN level_NN of_IN
          0_CD ._. 05_CD was_VBD used_VBN to_TO define_VB statistical_JJ significance_NN ._. Unless_IN otherwise_RB stated_VBN ,_, results_NNS are_VBP
          presented_VBN as_IN median_JJ (_( interquartile_NN range_NN )_) in_IN text_NN and_CC tables_NNS ._.
        
      
      
        Results_NNS
        
          Patient_NNP Flow_NNP and_CC Discontinuations_NNP
          Trial_NN patient_NN flow_NN is_VBZ summarized_VBD in_IN Figure_NN 1_CD ._. Between_IN August_NNP 2000_CD and_CC December_NNP 2003_CD ,_,
          42_CD patients_NNS at_IN the_DT Jonathan_NNP Lax_NNP Immune_NNP Disorder_NNP Clinic_NNP at_IN the_DT Philadelphia_NNP Field_NNP
          Initiating_NNP Group_NNP for_IN HIV_NNP Trials_NNP were_VBD enrolled_VBN ,_, randomized_JJ ,_, and_CC followed_VBD as_IN shown_VBN in_IN
          Figure_NN 2_CD ._. In_IN the_DT continuous_JJ therapy_NN /_NN single_JJ interruption_NN arm_NN ,_, 16_CD of_IN 21_CD patients_NNS reached_VBD
          the_DT open-ended_JJ interruption_NN ._. Reasons_NNS for_IN study_NN discontinuation_NN in_IN this_DT arm_NN were_VBD loss_NN to_TO
          follow-up_JJ (_(
          n_NN =_SYM 1_CD ;_: patient_NN moved_VBD away_RB )_) and_CC virological_JJ failure_NN during_IN continuous_JJ
          therapy_NN (_(
          n_NN =_SYM 4_CD ;_: further_RBR discussed_VBN below_IN )_) ._. In_IN the_DT repeated_VBN interruptions_NNS arm_NN ,_, 18_CD
          of_IN 21_CD patients_NNS reached_VBD the_DT open-ended_JJ interruption_NN following_VBG three_CD TIs_NNP of_IN 2_CD ,_, 4_CD ,_, and_CC 6_CD wk_NN
          duration_NN ,_, with_IN median_JJ peak_NN rises_VBZ in_IN viral_JJ loads_NNS of_IN 136_CD (_( 50_CD –_NN 2_CD ,_, 590_CD )_) ,_, 13_CD ,_, 651_CD (_( 180_CD –_NN 222_CD ,_, 589_CD )_) ,_,
          and_CC 18_CD ,_, 887_CD (_( 3_CD ,_, 893_CD –_NN 96_CD ,_, 101_CD )_) copies_NNS /_NN ml_NN ,_, respectively_RB ._. Median_JJ time_NN to_TO less_JJR than_IN 50_CD copies_NNS /_NN ml_NN
          after_IN resumption_NN of_IN therapy_NN was_VBD 2_CD (_( 0_CD –_NN 4_LS )_) ,_, 3_CD (_( 1_CD ._. 8_CD –_NN 12_CD )_) ,_, and_CC 9_CD ._. 5_CD (_( 2_CD –_NN 12_CD )_) wk_NN ,_, respectively_RB ,_,
          with_IN 9_CD ,_, 18_CD ,_, and_CC 20_CD wk_NN as_IN the_DT maximum_NN time_NN needed_VBN to_TO achieve_VB suppression_NN in_IN 100_CD %_NN of_IN
          patients_NNS before_IN reaching_VBG the_DT open-ended_JJ interruption_NN ._. Study_NN discontinuation_NN in_IN the_DT
          repeated_VBN interruptions_NNS arm_NN was_VBD due_JJ to_TO protocol_NN violation_NN (_(
          n_NN =_SYM 1_CD ;_: patient_NN restarted_VBD therapy_NN during_IN interruption_NN out_IN of_IN protocol_NN )_) ,_,
          loss_NN to_TO follow-up_JJ (_(
          n_NN =_SYM 1_CD ;_: patient_NN imprisoned_VBN )_) ,_, and_CC virological_JJ failure_NN during_IN on-therapy_JJ
          period_NN (_(
          n_NN =_SYM 1_CD ;_: further_RBR discussed_VBN below_IN )_) ._.
        
        
          Baseline_NNP Criteria_NNP and_CC Follow-_NNP Up_IN
          The_DT demographic_JJ and_CC clinical_JJ characteristics_NNS of_IN the_DT two_CD groups_NNS at_IN baseline_NN are_VBP
          summarized_VBD in_IN Table_NNP 1_CD ._. Seventy-five_NNP percent_NN of_IN participants_NNS were_VBD on_IN their_PRP$ second_JJ to_TO
          fourth_JJ regimen_NN while_IN 25_CD %_NN were_VBD in_IN their_PRP$ first_JJ regimen_NN
          ._. No_DT significant_JJ difference_NN was_VBD found_VBN in_IN baseline_NN parameters_NNS between_IN
          arms_NNS ,_, with_IN 33_CD %_NN –_NN 47_CD %_NN of_IN patients_NNS on_IN protease-inhibitor-containing_JJ and_CC 61_CD %_NN –_NN 71_CD %_NN on_IN
          NNRTI-containing_NNP regimens_NNS ._. Owing_NNP to_TO the_DT high_JJ participation_NN of_IN patients_NNS on_IN NNRTI-based_NNP
          regimens_NNS and_CC concerns_NNS about_IN TI_NNP and_CC safety_NN in_IN general_JJ ,_, patient_NN outcomes_NNS and_CC treatment_NN
          failure_NN were_VBD reviewed_VBN monthly_JJ by_IN the_DT IRB_NNP of_IN this_DT study_NN during_IN the_DT first_JJ 8_CD mo_NN of_IN study_NN ,_,
          quarterly_JJ for_IN the_DT following_VBG 4_CD mo_NN ,_, and_CC semi-annually_RB thereafter_RB ._. Figure_NN 2_CD shows_VBZ study_NN
          design_NN for_IN both_DT arms_NNS ,_, with_IN a_DT median_JJ follow-up_JJ of_IN 41_CD (_( 41_CD –_NN 42_CD )_) wk_NN during_IN phase_NN I_PRP for_IN the_DT
          continuous_JJ therapy_NN /_NN single_JJ interruption_NN arm_NN and_CC 42_CD (_( 30_CD –_NN 51_CD )_) wk_NN for_IN the_DT repeated_VBN
          interruptions_NNS arm_NN ._. Follow-up_JJ during_IN phase_NN II_NNP had_VBD a_DT median_JJ duration_NN of_IN 27_CD wk_NN in_IN both_DT arms_NNS
          (_( continuous_JJ therapy_NN /_NN single_JJ interruption_NN arm_NN ,_, 27_CD [_NN 8_CD ._. 75_CD –_NN 47_CD ]_NN ;_: repeated_VBN interruptions_NNS arm_NN ,_, 27_CD
          [_NN 16_CD ._. 5_LS –_NN 35_CD ]_NN )_) ._. Following_VBG reinitiation_NN of_IN therapy_NN after_IN phase_NN II_NNP ,_, patients_NNS suppressed_VBD viral_JJ
          replication_NN to_TO less_JJR than_IN 50_CD copies_NNS /_NN ml_NN by_IN a_DT median_JJ time_NN of_IN 10_CD (_( 6_CD –_NN 12_CD )_) wk_NN in_IN both_DT arms_NNS ,_,
          excluding_VBG for_IN two_CD patients_NNS in_IN the_DT continuous_JJ therapy_NN /_NN single_JJ interruption_NN arm_NN who_WP elected_VBD
          to_TO stay_VB off_RP ART_NNP indefinitely_RB and_CC one_CD patient_NN from_IN the_DT repeated_VBN interruptions_NNS arm_NN who_WP
          reported_VBD nonadherence_NN following_VBG regimen_NN reinitiation_NN yet_RB reached_VBD 52_CD copies_NNS /_NN ml_NN before_IN
          withdrawing_VBG from_IN additional_JJ follow-up_JJ ._.
        
        
          Primary_JJ Outcome_NNP
          An_DT intent-to-treat_JJ analysis_NN of_IN the_DT time_NN to_TO viral_JJ rebound_NN (_( >_NN 5_CD ,_, 000_CD copies_NNS /_NN ml_NN )_) in_IN the_DT
          open-ended_JJ interruption_NN showed_VBD no_DT difference_NN between_IN groups_NNS (_( continuous_JJ therapy_NN /_NN single_JJ
          TI_NNP ,_, median_JJ =_SYM 4_CD [_NN 1_CD –_NN 8_CD ]_NN wk_NN ,_, 
          n_NN =_SYM 21_CD ;_: repeated_VBN TI_NNP ,_, median_JJ =_SYM 5_CD [_NN 4_CD –_NN 8_CD ]_NN wk_NN ,_, 
          n_NN =_SYM 21_CD ;_: 
          p_NN =_SYM 0_CD ._. 36_CD )_) ._. Figure_NN 3_CD (_( top_JJ panel_NN )_) shows_VBZ the_DT probability_NN of_IN plasma_NN HIV-_NNP 1_CD
          RNA_NNP remaining_VBG less_JJR than_IN 5_CD ,_, 000_CD copies_NNS /_NN ml_NN for_IN the_DT two_CD groups_NNS (_(
          n_NN =_SYM 21_CD per_IN group_NN )_) ._. Exclusion_NNP of_IN drop-outs_JJ in_IN an_DT as-treated_JJ analysis_NN did_VBD
          not_RB alter_VB conclusions_NNS (_( single_JJ TI_NNP ,_, median_JJ =_SYM 5_CD [_NN 4_CD –_NN 9_CD ]_NN wk_NN ,_, 
          n_NN =_SYM 18_CD ;_: repeated_VBN TI_NNP ,_, median_JJ =_SYM 6_CD [_NN 4_CD –_NN 8_CD ]_NN wk_NN ,_, 
          n_NN =_SYM 16_CD ;_: 
          p_NN >_NN 0_CD ._. 05_CD )_) ._. Additional_JJ secondary_JJ analysis_NN of_IN the_DT magnitude_NN of_IN viral_JJ
          load_NN as_IN shown_VBN in_IN Figure_NN 3_CD (_( second_JJ panel_NN )_) showed_VBD similar_JJ viral_JJ replication_NN as_IN determined_VBN
          by_IN mean_NN AUC_NNP
          HIV_NNP RNA_NNP analysis_NN at_IN week_NN 12_CD (_( single_JJ TI_NNP ,_, median_JJ =_SYM 124_CD ,_, 621_CD
          [_NN 23_CD ,_, 326_CD –_NN 262_CD ,_, 348_CD ]_NN AUC_NNP
          HIV_NNP RNA_NNP ;_: repeated_VBN TI_NNP ,_, median_JJ =_SYM 100_CD ,_, 400_CD [_NN 47_CD ,_, 221_CD –_NN 365_CD ,_, 731_CD ]_NN AUC_NNP
          HIV_NNP RNA_NNP ;_: 
          p_NN >_NN 0_CD ._. 05_CD )_) or_CC week_NN 20_CD (_( single_JJ TI_NNP ,_, median_JJ =_SYM 114_CD ,_, 550_CD [_NN 31_CD ,_, 829_CD –_NN 362_CD ,_, 628_CD ]_NN
          AUC_NNP
          HIV_NNP RNA_NNP ;_: repeated_VBN TI_NNP ,_, median_JJ =_SYM 153_CD ,_, 097_CD [_NN 67_CD ,_, 427_CD –_NN 515_CD ,_, 421_CD ]_NN AUC_NNP
          HIV_NNP RNA_NNP ;_: 
          p_NN >_NN 0_CD ._. 05_CD )_) ._.
        
        
          Secondary_JJ Outcomes_NNP SAEs_NNP and_CC patient_NN discontinuation_NN
          No_DT patient_NN discontinuation_NN in_IN either_DT group_NN was_VBD due_JJ to_TO study-defined_JJ changes_NNS in_IN CD_NNP 4_CD
          cell_NN count_NN (_( reviewed_VBN further_RB below_IN )_) or_CC due_JJ to_TO study-associated_JJ SAEs_NNP (_( disease_NN progression_NN
          or_CC acute_JJ retroviral_NN syndrome_NN )_) ._. However_RB ,_, four_CD non-study-related_JJ SAEs_NNP occurred_VBD :_: two_CD
          patients_NNS from_IN the_DT continuous_JJ therapy_NN /_NN single_JJ interruption_NN arm_NN were_VBD hospitalized_VBN ,_, one_CD for_IN a_DT
          cholecystectomy_NN and_CC one_CD for_IN acute_JJ rectal_NN bleeding_NN ,_, during_IN the_DT 40_CD -_: wk_NN ART_NNP period_NN ;_: a_DT patient_NN
          from_IN the_DT repeated_VBN interruptions_NNS arm_NN died_VBD of_IN liver_NN cancer_NN during_IN week_NN 26_CD of_IN the_DT open-ended_JJ
          interruption_NN after_IN previously_RB reaching_VBG a_DT viral_JJ load_NN greater_JJR than_IN 5_CD ,_, 000_CD copies_NNS /_NN ml_NN yet_RB
          electing_VBG to_TO stay_VB off_RP ART_NNP ;_: and_CC a_DT patient_NN from_IN the_DT repeated_VBN interruptions_NNS arm_NN developed_VBD a_DT
          transient_JJ ileitis_NNS ._.
        
        
          Immune_NNP reconstitution_NN
          No_DT significant_JJ difference_NN was_VBD observed_VBN between_IN groups_NNS in_IN CD_NNP 4_CD T_NN cell_NN counts_VBZ at_IN the_DT
          start_NN of_IN phase_NN II_NNP ,_, as_IN illustrated_VBN in_IN Figure_NN 4_CD ._. In_IN addition_NN ,_, no_DT difference_NN in_IN the_DT
          percentage_NN of_IN naïve_NN CD_NNP 4_CD cells_NNS or_CC decrease_NN of_IN recall_NN response_NN to_TO 
          C_NNP ._. albicans_NNS was_VBD observed_VBN ,_, confirming_VBG the_DT absence_NN of_IN
          significant_JJ differences_NNS in_IN the_DT retention_NN of_IN baseline_NN immune_JJ reconstitution_NN correlates_NNS
          between_IN arms_NNS ._. However_RB ,_, a_DT significant_JJ decrease_NN in_IN the_DT abundance_NN of_IN CD_NNP 4_CD cells_NNS relative_JJ to_TO
          other_JJ T_NN cell_NN types_NNS as_IN summarized_VBD in_IN CD_NNP 4_CD %_NN (_( but_CC not_RB in_IN absolute_JJ CD_NNP 4_CD count_NN )_) was_VBD present_JJ in_IN
          the_DT repeated_VBN TI_NNP arm_NN ,_, corresponding_JJ to_TO a_DT significant_JJ increase_NN in_IN CD_NNP 8_CD T_NN cell_NN count_NN ._. In_IN
          spite_NN of_IN fluctuations_NNS in_IN CD_NNP 4_CD T_NN cell_NN count_NN levels_NNS between_IN the_DT start_NN and_CC end_VB of_IN each_DT
          monitored_VBN TI_NNP ,_, a_DT recovery_NN of_IN CD_NNP 4_CD count_NN levels_NNS was_VBD achieved_VBN upon_IN resuppression_NN following_VBG
          each_DT TI_NNP in_IN conjunction_NN with_IN a_DT retention_NN of_IN lymphoproliferative_JJ responses_NNS against_IN 
          C_NNP ._. albicans_NNS before_RB ,_, during_IN ,_, and_CC after_IN each_DT TI_NNP ,_, as_IN illustrated_VBN
          in_IN Figure_NN 5_CD ._.
        
        
          Viral_NNP resistance_NN mutations_NNS and_CC therapy_NN failure_NN
          An_DT intent-to-treat_JJ analysis_NN of_IN the_DT combined_VBN number_NN of_IN patients_NNS per_IN arm_NN with_IN detected_VBD
          resistance_NN mutations_NNS irrespective_RB of_IN therapy_NN failure_NN in_IN phase_NN I_PRP and_CC during_IN the_DT final_JJ TI_NNP
          in_IN phase_NN II_NNP showed_VBD no_DT significant_JJ difference_NN between_IN arms_NNS (_( continuous_JJ therapy_NN /_NN single_JJ TI_NNP ,_,
          7_CD /_NN 21_CD ;_: repeated_VBN TI_NNP ,_, 10_CD /_NN 21_CD ;_: 
          p_NN >_NN 0_CD ._. 05_CD )_) ._.
          Study-defined_NNP criteria_NNS for_IN therapy_NN failure_NN of_IN a_DT previously_RB suppressive_JJ regimen_NN were_VBD
          met_VBN by_IN 4_CD /_NN 21_CD patients_NNS in_IN the_DT continuous_JJ therapy_NN /_NN single_JJ interruption_NN arm_NN (_( patients_NNS S_NNP 37_CD ,_,
          S_NNP 47_CD ,_, S_NNP 52_CD ,_, and_CC S_NNP 59_CD )_) in_IN association_NN with_IN self-reported_JJ nonadherence_NN to_TO therapy_NN and_CC
          detection_NN of_IN resistance_NN mutations_NNS in_IN phase_NN I_PRP ,_, as_IN listed_VBN in_IN Table_NNP 2_CD ._. One_CD patient_NN in_IN the_DT
          repeated_VBN interruptions_NNS arm_NN (_( 1_CD /_NN 21_CD ;_: patient_NN S_NNP 56_CD )_) failed_VBD therapy_NN after_IN 20_CD wk_NN following_VBG the_DT
          third_JJ TI_NNP by_IN maintaining_VBG a_DT viral_JJ load_NN between_IN 50_CD and_CC 999_CD copies_NNS /_NN ml_NN in_IN the_DT presence_NN of_IN
          previously_RB undetected_JJ resistance_NN mutations_NNS ._.
          In_IN patients_NNS who_WP reached_VBD phase_NN II_NNP in_IN the_DT absence_NN of_IN therapy_NN failure_NN ,_, a_DT total_NN of_IN 12_CD
          patients_NNS were_VBD identified_VBN to_TO have_VB resistance_NN mutations_NNS at_IN the_DT first_JJ viremic_JJ time_NN point_NN
          (_( continuous_JJ therapy_NN /_NN single_JJ TI_NNP ,_, 3_CD /_NN 16_CD ;_: repeated_VBN TI_NNP ,_, 9_CD /_NN 18_CD ;_: 
          p_NN =_SYM 0_CD ._. 06_CD )_) ._. A_DT greater_JJR number_NN of_IN resistance_NN mutations_NNS was_VBD detected_VBN in_IN the_DT
          repeated_VBN interruption_NN arm_NN ,_, as_IN summarized_VBD in_IN Table_NNP 3_CD ._. In_IN ten_CD out_IN of_IN these_DT 12_CD patients_NNS ,_, a_DT
          change_NN in_IN resistance_NN patterns_NNS was_VBD observed_VBN when_WRB comparing_VBG the_DT first_JJ viremic_JJ time_NN point_NN to_TO
          the_DT last_NN ._. All_DT 11_CD of_IN 12_CD patients_NNS in_IN Table_NNP 3_CD who_WP reinitiated_JJ therapy_NN retained_VBD suppressive_JJ
          ability_NN of_IN their_PRP$ respective_JJ regimens_NNS ,_, as_IN did_VBD all_DT other_JJ patients_NNS who_WP did_VBD not_RB show_VB
          resistance_NN mutations_NNS in_IN phase_NN II_NNP ._. In_IN the_DT repeated_VBN interruptions_NNS arm_NN ,_, analysis_NN of_IN newly_RB
          detected_VBD resistance_NN mutations_NNS in_IN phase_NN II_NNP ,_, as_IN defined_VBN by_IN a_DT lack_NN of_IN detection_NN during_IN
          viremic_JJ time_NN points_NNS in_IN phase_NN I_PRP ,_, identified_VBD 3_CD /_NN 18_CD patients_NNS (_( patients_NNS S_NNP 4_CD ,_, S_NNP 22_CD ,_, and_CC S_NNP 43_CD )_) with_IN
          this_DT pattern_NN (_( see_VB notations_NNS in_IN Table_NNP 3_LS )_) ._.
        
      
      
        Discussion_NNP
        Earlier_JJR reports_NNS on_IN TI_NNP strategies_NNS in_IN patients_NNS with_IN chronic_JJ HIV_NNP infection_NN include_VBP multiple_JJ
        pilot_NN or_CC single-arm_JJ study_NN designs_NNS centered_VBN on_IN the_DT effects_NNS on_IN viral_JJ control_NN by_IN comparison_NN
        with_IN pre-therapy_JJ periods_NNS ,_, detection_NN of_IN resistance_NN mutations_NNS without_IN parallel_JJ follow-up_JJ of_IN a_DT
        continuously_RB treated_VBN arm_NN ,_, and_CC inclusion_NN of_IN variable_JJ criteria_NNS regarding_VBG viral_JJ resuppression_NN
        before_IN proceeding_VBG with_IN repeated_VBN TIs_NNP [_NN 11_CD ,_, 12_CD ,_, 14_CD ,_, 16_CD ]_NN ._. In_IN contrast_NN ,_, our_PRP$ strategy_NN mandated_VBD
        resuppression_NN of_IN viral_JJ replication_NN to_TO less_JJR than_IN 50_CD copies_NNS /_NN ml_NN before_IN each_DT TI_NNP and_CC presents_VBZ
        the_DT first_JJ comparison_NN of_IN viral_JJ replication_NN during_IN a_DT final_JJ open-ended_JJ interruption_NN of_IN therapy_NN
        between_IN patients_NNS randomized_JJ to_TO complete_VB three_CD sequential_NN TIs_NNP or_CC stay_VB under_IN continuous_JJ
        therapy_NN ._. Our_PRP$ data_NNS ,_, based_VBN on_IN intent-to-treat_JJ analysis_NN ,_, did_VBD not_RB show_VB that_WDT repeated_VBD TIs_NNP
        resulted_VBD in_IN a_DT clinically_RB significant_JJ virological_JJ benefit_NN as_IN measured_VBN by_IN the_DT time_NN to_TO viral_JJ
        rebound_NN to_TO more_JJR than_IN 5_CD ,_, 000_CD copies_NNS /_NN ml_NN (_( see_VB Figure_NN 3_LS )_) ._. Secondary_JJ as-treated_JJ analysis_NN on_IN viral_JJ
        replication_NN magnitude_NN also_RB indicated_VBD a_DT lack_NN of_IN difference_NN between_IN arms_NNS ._. Consistent_NNP with_IN the_DT
        findings_NNS of_IN SSITT_NNP [_NN 11_CD ]_NN ,_, analysis_NN of_IN our_PRP$ data_NNS by_IN the_DT categorical_JJ classification_NN of_IN a_DT
        “ responder_NN” as_IN a_DT patient_NN with_IN viral_JJ load_NN less_JJR than_IN 5_CD ,_, 000_CD copies_NNS /_NN ml_NN at_IN week_NN 12_CD off_IN therapy_NN
        showed_VBD no_DT significant_JJ difference_NN in_IN this_DT frequency_NN between_IN arms_NNS (_( single_JJ TI_NNP ,_, 5_CD /_NN 18_CD ;_: repeated_VBN
        TI_NNP ,_, 5_CD /_NN 16_CD )_) ,_, suggesting_VBG the_DT presence_NN of_IN “ responders_NNS” irrespective_RB of_IN previous_JJ
        protocol-mandated_JJ TIs_NNP ._.
        Based_VBN on_IN secondary_JJ outcome_NN measures_NNS ,_, the_DT incidence_NN of_IN adverse_JJ events_NNS (_( SAEs_NNP ,_, therapy_NN
        failure_NN ,_, and_CC patient_NN discontinuation_NN )_) or_CC clinical_JJ disease_NN progression_NN (_( as_IN indicated_VBN by_IN CD_NNP 4_CD
        count_NN on_IN therapy_NN or_CC opportunistic_JJ infections_NNS )_) was_VBD not_RB observed_VBN to_TO be_VB different_JJ between_IN
        arms_NNS ._. Prospective_JJ safety_NN outcomes_NNS in_IN our_PRP$ study_NN are_VBP in_IN accordance_NN with_IN reports_NNS from_IN a_DT
        retrospective_NN analysis_NN of_IN 1_CD ,_, 290_CD patients_NNS who_WP interrupted_VBN treatment_NN at_IN least_JJS once_RB (_( <_NN 3_CD
        mo_NN )_) without_IN an_DT increased_VBN risk_NN of_IN HIV-associated_NNP morbidity_NN or_CC mortality_NN (_( with_IN the_DT exception_NN
        of_IN patients_NNS in_IN Center_NNP for_IN Disease_NNP Control_NNP and_CC Prevention_NNP stage_NN C_NNP during_IN first_JJ interruption_NN
        only_RB )_) [_NN 21_CD ]_NN ._. In_IN regards_VBZ to_TO immunological_JJ outcomes_NNS ,_, a_DT concern_NN associated_VBN with_IN interruption_NN of_IN
        suppressive_JJ therapy_NN is_VBZ the_DT potential_NN for_IN irreversible_JJ ,_, viral-mediated_JJ CD_NNP 4_CD T_NN cell_NN loss_NN
        leading_VBG to_TO disease_NN progression_NN [_NN 6_CD ,_, 22_CD ]_NN ._. We_PRP did_VBD not_RB observe_VB a_DT decrease_NN in_IN CD_NNP 4_CD cell_NN numbers_NNS or_CC
        lymphoproliferative_JJ responses_NNS against_IN 
        C_NNP ._. albicans_NNS when_WRB measured_VBN between_IN arms_NNS before_IN the_DT open-ended_JJ TI_NNP
        (_( see_VB Figure_NN 4_LS )_) ,_, nor_CC following_VBG resuppression_NN after_IN monitored_VBN TI_NNP reinitiation_NN cycles_NNS in_IN the_DT
        repeated_VBN interruptions_NNS arm_NN (_( see_VB Figure_NN 5_LS )_) ._. The_DT latter_NN is_VBZ consistent_JJ with_IN observations_NNS by_IN
        others_NNS and_CC does_VBZ not_RB support_VB an_DT immediate_JJ immunological_JJ “ cost_NN” to_TO short-term_JJ TIs_NNP
        [_NN 12_CD ,_, 14_CD ,_, 15_CD ,_, 16_CD ,_, 23_CD ]_NN ._. However_RB ,_, we_PRP do_VBP show_VB that_IN monitoring_VBG CD_NNP 4_CD cell_NN numbers_NNS by_IN percentage_NN could_MD
        lead_VB to_TO misinterpreting_VBG a_DT significant_JJ loss_NN of_IN CD_NNP 4_CD cells_NNS as_IN a_DT result_NN of_IN a_DT significant_JJ
        increase_NN in_IN CD_NNP 8_CD count_NN following_VBG TIs_NNP ,_, even_RB though_IN absolute_JJ CD_NNP 4_CD count_NN numbers_NNS remained_VBD
        unchanged_JJ (_( see_VB Figure_NN 4_LS )_) ._. Interestingly_RB ,_, the_DT increase_NN in_IN CD_NNP 8_CD T_NN cell_NN number_NN also_RB
        corresponded_VBD with_IN an_DT increase_NN in_IN HIV-specific_NNP responses_NNS as_IN measured_VBN by_IN interferon-gamma_JJ
        expression_NN (_( data_NNS not_RB shown_VBN )_) ,_, which_WDT in_IN light_NN of_IN an_DT absence_NN of_IN effect_NN on_IN viral_JJ load_NN between_IN
        arms_NNS further_JJ supports_NNS that_IN TI_NNP strategies_NNS alone_RB may_MD not_RB significantly_RB alter_VB the_DT pre-existing_JJ
        balance_NN between_IN viral_JJ replication_NN and_CC host_VB antiviral_JJ responses_NNS [_NN 14_CD ,_, 16_CD ,_, 23_CD ,_, 24_CD ]_NN ._.
        Importantly_NNP ,_, no_DT evidence_NN for_IN an_DT increase_NN of_IN viral_JJ resistance_NN in_IN association_NN with_IN therapy_NN
        failure_NN was_VBD present_JJ in_IN the_DT repeated_VBN interruptions_NNS arm_NN (_( See_VB Table_NNP 2_LS )_) ._. We_PRP did_VBD not_RB observe_VB a_DT
        greater_JJR clinical_JJ failure_NN of_IN NNRTI-based_NNP regimens_NNS in_IN the_DT repeated_VBN interruption_NN arm_NN due_JJ to_TO
        “ single_VB drug_NN” periods_NNS as_IN predicted_VBN by_IN recently_RB redefined_VBD drug_NN half-life_NN estimates_NNS and_CC the_DT
        presence_NN of_IN viral_JJ replication_NN during_IN each_DT interruption_NN [_NN 25_CD ,_, 26_CD ,_, 27_CD ]_NN ._. However_RB ,_, the_DT percentage_NN
        of_IN patients_NNS with_IN resistance_NN mutations_NNS detected_VBD in_IN this_DT study_NN in_IN the_DT repeated_VBN interruption_NN
        arm_NN (_( 47_CD %_NN )_) is_VBZ higher_JJR than_IN the_DT 17_CD %_NN observed_VBD in_IN the_DT SSITT_NNP cohort_NN [_NN 11_CD ]_NN ,_, in_IN which_WDT patients_NNS with_IN
        prior_JJ treatment_NN failures_NNS were_VBD excluded_VBN [_NN 28_CD ]_NN ._. We_PRP interpret_VBP this_DT difference_NN to_TO mean_VB that_IN the_DT
        resistance_NN detected_VBD off_IN drug_NN in_IN both_DT our_PRP$ and_CC their_PRP$ cohorts_NNS is_VBZ likely_RB associated_VBN with_IN the_DT
        greater_JJR number_NN of_IN drug-experienced_JJ patients_NNS in_IN our_PRP$ cohort_NN (_( 75_CD %_NN )_) and_CC the_DT detection_NN of_IN prior_JJ
        archived_JJ resistance_NN mutations_NNS as_IN supported_VBN by_IN Metzner_NNP et_CC al_NN ._. [_NN 29_CD ]_NN ,_, who_WP documented_VBN in_IN 14_CD /_NN 25_CD
        (_( 56_CD %_NN )_) SSITT_NNP patients_NNS the_DT presence_NN of_IN minor_JJ populations_NNS of_IN M_NNP 184_CD V_NNP occurring_VBG at_IN least_JJS once_RB off_IN
        drug_NN during_IN interruption_NN of_IN therapy_NN ._.
        In_IN spite_NN of_IN the_DT lack_NN of_IN difference_NN in_IN the_DT total_JJ number_NN of_IN patients_NNS with_IN resistant_JJ
        mutations_NNS detected_VBD on_IN therapy_NN during_IN phase_NN I_PRP and_CC off_IN therapy_NN in_IN phase_NN II_NNP (_( 7_CD /_NN 21_CD [_NN 33_CD %_NN ]_NN versus_CC
        10_CD /_NN 21_CD [_NN 47_CD %_NN ]_NN ,_, respectively_RB )_) in_IN both_DT arms_NNS ,_, we_PRP do_VBP report_VB in_IN similarity_NN to_TO others_NNS a_DT greater_JJR
        detection_NN of_IN resistance_NN mutations_NNS in_IN the_DT TI_NNP arm_NN when_WRB restricting_VBG analysis_NN to_TO the_DT last_JJ
        off-drug_JJ period_NN only_RB [_NN 29_CD ,_, 30_CD ]_NN as_IN three_CD of_IN 16_CD (_( 18_CD %_NN )_) had_VBD mutations_NNS detected_VBN off_IN drug_NN in_IN the_DT
        continuous_JJ therapy_NN /_NN single_JJ interruption_NN arm_NN compared_VBN to_TO nine_CD of_IN 18_CD (_( 50_CD %_NN )_) in_IN the_DT repeated_VBN
        interruption_NN arm_NN ._. However_RB ,_, based_VBN on_IN the_DT lack_NN of_IN association_NN between_IN viral_JJ resistance_NN
        detected_VBD off-drug_JJ shortly_RB after_IN TI_NNP and_CC resuppression_NN by_IN the_DT same_JJ regimen_NN in_IN all_DT patients_NNS ,_,
        it_PRP remains_VBZ undetermined_JJ to_TO what_WP extent_NN TIs_NNP favor_NN the_DT detection_NN of_IN archived_JJ mutations_NNS in_IN
        chronically_RB suppressed_VBN patients_NNS and_CC to_TO what_WP extent_NN these_DT mutations_NNS are_VBP a_DT signal_NN for_IN a_DT
        future_JJ therapy_NN failure_NN ._. The_DT latter_NN is_VBZ best_RBS exemplified_VBN by_IN the_DT data_NNS we_PRP collected_VBD on_IN patients_NNS
        on_IN NNRTI-based_NNP regimens_NNS in_IN the_DT repeated_VBN interruptions_NNS arm_NN where_WRB two_CD patients_NNS (_( S_NNP 19_CD and_CC S_NNP 43_CD )_)
        showed_VBD K_NNP 103_CD N_NNP detection_NN (_( only_RB during_IN the_DT off-drug_JJ periods_NNS )_) in_IN the_DT absence_NN of_IN therapy_NN failure_NN
        while_IN maintaining_VBG the_DT same_JJ regimen_NN after_IN each_DT TI_NNP ,_, including_VBG post-study_JJ follow-up_JJ (_( Table_NNP
        S_NNP 1_LS )_) ._. On_IN the_DT other_JJ hand_NN ,_, virological_JJ failure_NN in_IN the_DT continued_VBN presence_NN of_IN an_DT NNRTI-based_NNP
        regimen_NN in_IN phase_NN I_PRP was_VBD associated_VBN with_IN detection_NN of_IN K_NNP 103_CD N_NNP ,_, as_IN observed_VBN in_IN one_CD patient_NN (_( S_NNP 56_CD )_)
        in_IN the_DT repeated_VBN interruption_NN arm_NN and_CC three_CD patients_NNS (_( S_NNP 37_CD ,_, S_NNP 52_CD ,_, and_CC S_NNP 59_CD )_) in_IN the_DT continuous_JJ
        therapy_NN arm_NN with_IN self-reported_JJ non-adherence_JJ ._.
        Drug_NN resistance_NN that_WDT occurs_VBZ during_IN virological_JJ drug_NN failure_NN predicts_VBZ virological_JJ
        responses_NNS to_TO salvage_VB treatment_NN [_NN 31_CD ,_, 32_CD ,_, 33_CD ]_NN ._. In_IN contrast_NN ,_, the_DT clinical_JJ implications_NNS of_IN drug_NN
        resistance_NN mutations_NNS that_WDT appear_VBP shortly_RB after_IN TI_NNP in_IN chronically_RB suppressed_VBN patients_NNS are_VBP
        not_RB clear_JJ ._. Case_NN reports_NNS in_IN this_DT cohort_NN of_IN patients_NNS have_VBP demonstrated_VBN that_IN drug-resistant_JJ
        variants_NNS that_WDT appeared_VBD during_IN TIs_NNP may_MD not_RB persist_VB in_IN subsequent_JJ time_NN points_NNS even_RB after_IN
        repeated_VBN use_NN of_IN the_DT same_JJ antiretroviral_NN regimen_NN [_NN 19_CD ,_, 34_CD ]_NN ._. We_PRP now_RB observe_VBP that_DT drug_NN
        resistance_NN appearing_VBG during_IN TIs_NNP can_MD be_VB transient_JJ since_IN 50_CD %_NN and_CC 33_CD %_NN of_IN patients_NNS listed_VBN in_IN
        Table_NNP 3_CD showed_VBD complete_JJ and_CC partial_JJ reversion_NN to_TO wild_JJ type_NN ,_, respectively_RB ,_, when_WRB comparing_VBG to_TO
        resistance_NN at_IN the_DT last_JJ available_JJ viremic_JJ time_NN point_NN in_IN phase_NN II_NNP (_( See_NNP Table_NNP 3_LS )_) ._. Further_RB ,_, we_PRP
        observed_VBD durable_JJ resuppression_NN of_IN plasma_NN viral_JJ RNA_NNP level_NN in_IN many_JJ patients_NNS who_WP had_VBD
        drug-resistance_JJ mutations_NNS off_IN therapy_NN that_WDT would_MD otherwise_RB be_VB expected_VBN to_TO affect_VB part_NN of_IN
        their_PRP$ treatment_NN regimen_NN when_WRB reinitiated_JJ (_( see_VB Table_NNP S_NNP 1_LS )_) ._. Virus_NNP populations_NNS that_WDT expand_VBP
        shortly_RB after_IN TI_NNP may_MD lack_NN all_DT of_IN the_DT adaptations_NNS required_VBN to_TO achieve_VB high_JJ levels_NNS of_IN plasma_NN
        viremia_NN in_IN the_DT presence_NN of_IN drug_NN during_IN continuous_JJ treatment_NN ._. These_DT adaptations_NNS may_MD include_VB
        the_DT resistance-associated_JJ mutations_NNS ,_, which_WDT were_VBD detected_VBN ,_, as_RB well_RB as_IN secondary_JJ mutations_NNS
        that_WDT may_MD increase_VB the_DT viral_JJ replication_NN capacity_NN [_NN 35_CD ,_, 36_CD ]_NN or_CC envelope_NN adaptations_NNS required_VBN
        to_TO escape_VB concurrent_JJ humoral_NN immune_JJ responses_NNS [_NN 37_CD ,_, 38_CD ]_NN ._. It_PRP is_VBZ of_IN interest_NN to_TO note_VB that_IN
        despite_IN the_DT large_JJ amount_NN of_IN research_NN activity_NN on_IN TIs_NNP in_IN patients_NNS with_IN suppressed_VBN chronic_JJ
        infection_NN and_CC the_DT hundreds_NNS of_IN monitored_VBN interruptions_NNS studied_VBN to_TO date_NN ,_, only_RB limited_JJ cases_NNS
        of_IN development_NN of_IN clinical_JJ resistance_NN (_( as_IN evidenced_VBN by_IN a_DT lack_NN of_IN viral_JJ resuppression_NN
        following_VBG therapy_NN reinitiation_NN )_) have_VBP emerged_VBN ,_, in_IN contrast_NN to_TO the_DT multiple_JJ reports_NNS of_IN
        detection_NN of_IN viral_JJ sequences_NNS off_RP ART_NNP associated_VBN with_IN resistance_NN as_IN shown_VBN in_IN this_DT study_NN and_CC
        others_NNS [_NN 11_CD ,_, 19_CD ,_, 29_CD ,_, 30_CD ,_, 39_CD ,_, 40_CD ]_NN ._.
        Taken_VBN together_RB ,_, while_IN our_PRP$ data_NNS show_VBP no_DT clinically_RB significant_JJ benefit_NN for_IN repeated_VBN TIs_NNP
        of_IN less_JJR than_IN 1_CD ._. 5_CD mo_NN in_IN patients_NNS with_IN CD_NNP 4_CD counts_VBZ greater_JJR than_IN 400_CD on_IN therapy_NN with_IN regard_NN to_TO
        viral_JJ control_NN as_IN defined_VBN by_IN time_NN to_TO rebound_VB ,_, secondary_JJ outcomes_NNS document_NN no_DT significant_JJ
        difference_NN in_IN levels_NNS of_IN retention_NN of_IN immune_JJ reconstitution_NN between_IN arms_NNS and_CC no_DT increased_VBN
        incidence_NN of_IN virological_JJ failure_NN as_IN a_DT consequence_NN of_IN TIs_NNP ._. While_IN our_PRP$ data_NNS indicate_VBP that_IN this_DT
        TI_NNP strategy_NN should_MD not_RB be_VB pursued_VBN outside_IN of_IN a_DT clinical_JJ trial_NN setting_NN ,_, we_PRP argue_VBP that_IN it_PRP
        will_MD be_VB important_JJ to_TO collect_VB additional_JJ data_NNS on_IN the_DT potential_JJ benefits_NNS of_IN drug-sparing_JJ
        regimens_NNS (_( such_JJ as_IN reduced_VBN long-term_JJ toxicity_NN and_CC reduced_VBN cost_NN )_) and_CC to_TO define_VB long-term_JJ
        outcomes_NNS in_IN comparison_NN with_IN continuous_JJ therapy_NN ._.
      
      
        Supporting_VBG Information_NNP
        Registration_NNP of_IN randomized_JJ trial_NN at_IN clinicaltrials_NNS ._. gov_NN under_IN identifier_NN NCT_NNP 00051818_CD ._.
      
    
  
